|

Emi-Le Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Day One Biopharmaceuticals, Inc.1

Indications

  • Primary Peritoneal Cavity Cancer1
  • Adenoid Cystic Carcinoma1
  • Fallopian Tube Cancer1
  • Triple Negative Breast Cancer1
  • Endometrial Cancer1

Phoenix, Arizona1 trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.